Moderna, Inc. (MRNA) Stock

About Moderna, Inc.

Moderna, Inc., a biotechnology firm, is dedicated to the discovery, development, and commercialization of messenger RNA (mRNA) based therapies and preventive medicines. Its extensive research and development efforts target a broad spectrum of medical needs, including infectious diseases, cancer immunology, rare conditions, cardiovascular ailments, and autoimmune disorders, with operations spanning the United States, Europe, and other global markets. The company's diverse product pipeline encompasses various vaccine candidates: those for respiratory illnesses like COVID-19, influenza, and respiratory syncytial virus (RSV); latent viral infections such as cytomegalovirus (CMV), Epstein-Barr virus (EBV), human immunodeficiency virus (HIV), herpes simplex virus (HSV), and varicella-zoster virus (VZV); and public health threats like Zika and Nipah. Additionally, Moderna is advancing systemic secreted and cell surface-targeted therapeutics, an array of cancer vaccines (including personalized, KRAS, and checkpoint varieties), intratumoral immuno-oncology products, localized regenerative treatments, systemic intracellular medicines, and inhaled pulmonary solutions. Moderna maintains strategic alliances with several prominent entities, including AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, Carisma Therapeutics, Inc., Metagenomi, Inc., the Defense Advanced Research Projects Agency (DARPA), the Biomedical Advanced Research and Development Authority (BARDA), the Institute for Life Changing Medicines, and The Bill & Melinda Gates Foundation. It also holds a collaboration and license agreement with Chiesi Farmaceutici S.P.A. Founded in 2010 as Moderna Therapeutics, Inc., the company officially became Moderna, Inc. in August 2018. Its corporate headquarters are located in Cambridge, Massachusetts.

Moderna, Inc. is led by CEO Stéphane Bancel, employs 5,800 people, headquartered in Cambridge, US, publicly traded since 2018.

Moderna, Inc. (MRNA) stock trades at $55.57 with a market capitalization of $22.05B. The stock is valued at a price-to-earnings (P/E) ratio of -12.82, price-to-book of 2.43, price-to-sales of 8.75. Over the past 52 weeks the stock has ranged between $22.28 and $85.32, and currently trades 34.9% below its 52-week high.

On profitability, Moderna, Inc. generates a return on equity (ROE) of -36.56%, return on capital employed of -35.54%, an operating margin of -1.31%, a net profit margin of -1.44%.

In its most recent fiscal year, Moderna, Inc. reported annual revenue of $1.9B, net profit of $-2.8B, revenue has compounded at 19.3% a year over the last five years.

The balance sheet shows a debt-to-equity ratio of 0.18 — a conservative balance sheet with little leverage risk, a current ratio of 2.41, total assets of $12.3B, $2.6B in cash and equivalents.

MRNA has an average daily trading volume of 7,733,206 shares, a beta of 1.03.

Official website: www.modernatx.com